==== June 2016 Call Notes ====

|~~TABLE_CELL_WRAP_START~~<WRAP>
Attendees: Nils Gehlenborg, Lisa Chadwick, Olivier Blondel, Stephanie Alexander, Timothee Lionett, Iddil Bekirov (Notes: Matt Roy, HMS)

\__

Introductory conversation regarding having a structure to improve policy meeting input/feedback

1) Feedback on publication policy

  * Is intellectual property respectfully credited within the 4DN?
  * How can we assure the consortium is most productive to our mission while respecting rights in academia
      * How will policies be approved?
        * Chair of the Policy Working Group (WG) will present findings to the Steering Committee(SC) for consensus. \__The Working group will then vote on the SC’s findings
        * Chair needs feedback for the policy to have it appease the entire consortium and pass through

2) Regarding the expectation to send software published before data

  * Releasing the IP of trainees could endanger career path
  * \__While for internal use only, data documentation needs to be prioritized  and manuscript tracking may be inadequate
  * Action item: provide clear policy guidelines with data from 4DN programs office for regulation assurance of sensitive software
      * Add preface lines to this guidelines remind consortium of its mission
        * Great policy will provide for reassuring regulatory operations to protect IP
      * \__Remind consortium of need to share and collaborate
  * Need to be sure to not allow conflicts of interest in reviewing of articles that had accessible information through consortium
      * Not a foreseeable conflict at this time

3) Other business: Availability Imaging data

  * Undecided if feasible to provide all imaging data publicly or to make it accessible via request
  * Is there a way to create a commons or forum in an accessible shape such that biological conclusions could be drawn?
  * Could the consortium gain access on an efficient timeline to share vital imaging data?
      * At such time, can’t imaging be made public to open
        * While both genomic and imaging data need to be made public as quickly as possible, though how to best outline policy
  * How can embargoes most effectively protect IP of all members while allowing research to benefit

</WRAP>~~TABLE_CELL_WRAP_STOP~~|